New & Noteworthy

Dec 30, 2017
Pharmaceutical Executive
Pharm Exec details the latest approaches to combating disease and health crises on a global scale—including industry perspectives from those involved on the front lines.
Dec 29, 2017
Pharmaceutical Executive
Amid a widening net of health threats worldwide, alliances forged in research and response may be more critical than ever to stem the tide.
Dec 22, 2017
Kilian Weiss talks to Pharm Exec about the modern challenges of identifying KOLs in oncology, and why technology can offer a solution to this vital process.
Dec 18, 2017
Pharmaceutical Executive
With over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit marketing to reduce the prescription and over-prescription of opioids.
Dec 12, 2017
Pharmaceutical Executive
Figuring out the right formula to address global health—for the better.
Dec 11, 2017
Pharmaceutical Executive
Groundbreaking treatment approaches call for innovative commercialization strategies.
Dec 11, 2017
Pharmaceutical Executive
In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.
Dec 10, 2017
Pharmaceutical Executive
How Ruud Dobber is steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.
Dec 05, 2017
Pharmaceutical Executive
Innovation by itself won't solve the complex multichannel challenges pharmas face. Jeff Greene reports.
Nov 30, 2017
Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.
native1_300x100
lorem ipsum